Trials / Completed
CompletedNCT02881216
Procedural Advantages of a Novel Drug-Eluting Coronary Stent
Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 814 (actual)
- Sponsor
- University Hospital Heidelberg · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Synergy Stent | Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation. |
| DEVICE | Currently common drug-eluting stent (DES) | Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus) |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-12-01
- Completion
- 2016-06-01
- First posted
- 2016-08-26
- Last updated
- 2016-08-29
Source: ClinicalTrials.gov record NCT02881216. Inclusion in this directory is not an endorsement.